UWVCGRJTVMQHJD-UHFFFAOYSA-N
C41H27BrF6N8O5S2 — CID 161215661
Data last refreshed: (MolForge compound catalog, from PubChem)
About UWVCGRJTVMQHJD-UHFFFAOYSA-N
UWVCGRJTVMQHJD-UHFFFAOYSA-N (PubChem CID 161215661) has the molecular formula C41H27BrF6N8O5S2 and a molecular weight of 969.74 g/mol. Its IUPAC name is 1-[2-bromo-4-(trifluoromethyl)phenyl]-N-pyrimidin-4-ylisoquinoline-6-sulfonamide;1-[2-methoxy-4-(trifluoromethyl)phenyl]-N-pyrimidin-4-ylisoquinoline-6-sulfonamide.
Molecular Properties
| Compound Name | UWVCGRJTVMQHJD-UHFFFAOYSA-N |
|---|---|
| PubChem CID | 161215661 |
| Molecular Formula | C41H27BrF6N8O5S2 |
| Molecular Weight | 969.74 g/mol |
| Exact Mass | 968.06 |
| IUPAC Name | 1-[2-bromo-4-(trifluoromethyl)phenyl]-N-pyrimidin-4-ylisoquinoline-6-sulfonamide;1-[2-methoxy-4-(trifluoromethyl)phenyl]-N-pyrimidin-4-ylisoquinoline-6-sulfonamide |
| SMILES | COc1cc(C(F)(F)F)ccc1-c1nccc2cc(S(=O)(=O)Nc3ccncn3)ccc12.O=S(=O)(Nc1ccncn1)c1ccc2c(-c3ccc(C(F)(F)F)cc3Br)nccc2c1 |
| InChI | InChI=1S/C21H15F3N4O3S.C20H12BrF3N4O2S/c1-31-18-11-14(21(22,23)24)2-4-17(18)20-16-5-3-15(10-13(16)6-9-26-20)32(29,30)28-19-7-8-25-12-27-19;21-17-10-13(20(22,23)24)1-3-16(17)19-15-4-2-14(9-12(15)5-8-26-19)31(29,30)28-18-6-7-25-11-27-18/h2-12H,1H3,(H,25,27,28);1-11H,(H,25,27,28) |
| InChIKey | UWVCGRJTVMQHJD-UHFFFAOYSA-N |
| XLogP | 9.79 |
| TPSA | 178.91 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 11 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 63 |
| Complexity | — |
Lipinski Rule of Five
3 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 969.74 |
| LogP ≤ 5 | 9.79 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 11 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 161215661 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.